<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04831398</url>
  </required_header>
  <id_info>
    <org_study_id>13084</org_study_id>
    <nct_id>NCT04831398</nct_id>
  </id_info>
  <brief_title>The Effects of Acute Melatonin Supplementation on Cardiovascular Responses to Sympathetic Activation</brief_title>
  <official_title>The Effects of Acute Melatonin Supplementation on Cardiovascular Responses to Sympathetic Activation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oklahoma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Oklahoma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      the purpose of this experiment is to determine if acute melatonin supplementation alters&#xD;
      central and peripheral cardiovascular responses to a cold pressor test at rest and during&#xD;
      dynamic exercise.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After IRB approval, experiments will take place in the Human Circulation Research Laboratory&#xD;
      in the Department of Health and Exercise on the University of Oklahoma Norman campus. All&#xD;
      subjects will complete a total of 3 visits. The first is a screening and time control visit&#xD;
      to provide informed consent and to ensure the potential participant meets all inclusion&#xD;
      criteria and no exclusion criteria. Once consented and enrolled, participants will complete a&#xD;
      time control trial (CON). On separate days (visits 2 and 3), participants will complete&#xD;
      placebo (PLA) and melatonin (MEL) in a randomly ordered, single-blind, counter-balanced&#xD;
      design. PLA or MEL treatment will precede testing by 30min to maximize absorption into the&#xD;
      circulation (Bartoli, 2013).&#xD;
&#xD;
      All experiments (CON/PLA/MEL) will begin with the subject lying supine for 5 min of quiet&#xD;
      rest where baseline measurements are taken, followed by their left foot being passively&#xD;
      placed in the iced water to complete a cold pressor test (CPT). Following the CPT&#xD;
      participants will be given 10 minutes of rest to recover all variables to pre-CPT values.&#xD;
      After which participants will be given a hand grip dynamometer to complete 7 minutes of&#xD;
      exercise at an intensity of 20% MVC at a 1s contraction to 2s relaxation cycle paced by a&#xD;
      metronome. During the final 2 minutes of the 7 minutes of exercise the participant's right&#xD;
      foot will be placed in the iced water such that the participant will be completing a CPT&#xD;
      during rhythmic grip exercise. After the completion of exercise, the subject will remain&#xD;
      supine for 10min. Then the a Total Labile Signal (TLS) procedure will be conducted. Where the&#xD;
      experimental limb is occluded using a blood pressure cuff for 5min. The cuff is then rapidly&#xD;
      deflated. The lowest oxyhemoglobin measured during the occlusion is recorded. After the TLS&#xD;
      procedure, the subject will be de-instrumented and will leave the laboratory.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">May 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>This study is a single-blind crossover design.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Participants will be blinded in two trials. Practitioners and operators will not be allowed to communicate with the participants concerning whether they are receiving placebo/melatonin. Outcome assessors and statisticians may not be blinded to experimental allocation. Our placebo should satisfy two conditions of an ideal placebo: a) it should be indistinguishable from the experimental supplement to blinded participants, and b) it should be physiologically inert. In this study, 1 microliter McCormicks Pure Mint Extract will be mixed with 29 ml of filtered water and given to participants as a sublingual spray. This mixture will be non-caloric and will mimic the taste and sensation of the commercially available melatonin spray that will be used in the study (Onnit Labs Inc., Mint Flavor).</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Muscle Tissue Oxygenation</measure>
    <time_frame>7 minutes of rest and 7 minutes of exercise</time_frame>
    <description>Concentrations of Total, Oxy, and deoxyhemoglobin of Flexor Digitorum Profundus muscle of the forearm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Arterial Pressure</measure>
    <time_frame>7 minutes of rest and 7 minutes of exercise</time_frame>
    <description>average pressure within the arteries</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cerebral Oxygenation</measure>
    <time_frame>7 minutes of rest and 7 minutes of exercise</time_frame>
    <description>Concentrations of Total, Oxy, and deoxyhemoglobin of the Prefrontal Cortex of the brain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate</measure>
    <time_frame>7 minutes of rest and 7 minutes of exercise</time_frame>
    <description>number of heart beats per minute</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory Rate</measure>
    <time_frame>7 minutes of rest and 7 minutes of exercise</time_frame>
    <description>number of breaths per minute</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Output</measure>
    <time_frame>7 minutes of rest and 7 minutes of exercise</time_frame>
    <description>volume of blood pumped by the heart per minute</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke Volume</measure>
    <time_frame>7 minutes of rest and 7 minutes of exercise</time_frame>
    <description>volume of blood pumped by the heart per heart beat</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total peripheral resistance</measure>
    <time_frame>7 minutes of rest and 7 minutes of exercise</time_frame>
    <description>amount of force affecting resistance to blood flow throughout the circulatory system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate Variability</measure>
    <time_frame>7 minutes of rest and 7 minutes of exercise</time_frame>
    <description>measure of the variation in time between each heart beat</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Time control experiment (CON). Nothing given to subject</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (PLA) is 10 sublingual sprays of a diluted (1 microliter/29ml filtered water) mint extract.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Melatonin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5mg commercially available melatonin (MEL) spray will be given sublingually.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>melatonin</intervention_name>
    <description>A 5mg dose of melatonin spay will be delivered sublingually.</description>
    <arm_group_label>Melatonin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>10 sprays of diluted mint extract. This mimics the sensation and taste of the melatonin spray</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>subject is given nothing</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy men and women&#xD;
&#xD;
          -  Women must be premenopausal with a regular menstrual cycle (26-30 days)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of autonomic dysfunction&#xD;
&#xD;
          -  Cardiovascular diseases&#xD;
&#xD;
          -  Diabetes&#xD;
&#xD;
          -  Tobacco/nicotine use&#xD;
&#xD;
          -  Systolic Pressure &gt;= 130 mmHg&#xD;
&#xD;
          -  Diastolic Pressure &gt;= 85 mmHg&#xD;
&#xD;
          -  Regular melatonin use &gt;= 1 use/week&#xD;
&#xD;
          -  Allergy to melatonin&#xD;
&#xD;
          -  Cardiometabolic medication use (e.g. anti-hypertensives, insulin-sensitizing, statins)&#xD;
&#xD;
          -  Sex hormone replacement medical use (e.g. testosterone, estrogen, progesterone)&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeremy M Kellawan</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oklahoma</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeremy M Kellawan, PhD</last_name>
    <phone>405 325 9028</phone>
    <email>kellawan@ou.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yair Pincu</last_name>
    <email>ypincu@ou.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Health and Exercise Science</name>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <zip>73019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 1, 2021</study_first_submitted>
  <study_first_submitted_qc>April 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2021</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Oklahoma</investigator_affiliation>
    <investigator_full_name>Jeremy Mikhail Kellawan</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The is no plan to share IPD</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

